Related Experiment Videos
Growth hormone therapy and lipid profile in children on chronic peritoneal dialysis
Antoni Jedrzejowski1, Małgorzata Pańczyk-Tomaszewska, Maria Roszkowska-Blaim
1Department of Pediatrics and Nephrology, Medical University of Warsaw, Marszałkowska 24, 00-576 Warsaw, Poland. antoni.jedrzejowski@parexel.com
Insights
Recombinant human growth hormone (rhGH) treatment in children undergoing peritoneal dialysis caused a temporary rise in triglyceride levels. However, rhGH did not significantly alter other serum lipid profiles in these patients.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Biochemistry
Background:
- Children with chronic kidney disease often experience growth failure.
- Peritoneal dialysis (PD) is a common treatment for pediatric end-stage renal disease.
- Growth hormone therapy is used to address growth deficits in various pediatric conditions.
Purpose of the Study:
- To evaluate the impact of recombinant human growth hormone (rhGH) on serum lipid profiles in children with chronic peritoneal dialysis.
- To determine if rhGH affects key lipid parameters including cholesterol, triglycerides, and apolipoproteins.
Main Methods:
- A 6-month prospective study involving 26 children (aged 5-18 years) on chronic peritoneal dialysis.
- 13 patients received rhGH (1-1.1 IU/kg/week), while 13 served as a control group.
- Serum levels of total cholesterol, LDL-C, HDL-C, triglycerides, apolipoproteins A-I and B-100, and lipoprotein (a) were measured at baseline and at 1, 3, and 6 months.
Main Results:
- A significant transient increase in serum triglyceride (TG) levels was observed at 1 month in the rhGH-treated group compared to baseline and controls (P<0.05 and P<0.001, respectively).
- No significant changes were detected in serum total cholesterol (TC), LDL-C, HDL-C, apoA, or Lp(a) levels throughout the 6-month treatment period.
- Serum urea, creatinine, total protein, and albumin levels remained unchanged in both groups.
Conclusions:
- rhGH administration in children with chronic peritoneal dialysis leads to a temporary elevation in serum triglyceride levels.
- rhGH does not appear to adversely affect other major serum lipid parameters (TC, LDL-C, HDL-C, apoA, Lp(a)) in this patient population.
- The findings suggest careful monitoring of triglyceride levels may be warranted during rhGH therapy in children on peritoneal dialysis.
Abstract:
The aim of the study was to assess the effect of recombinant human growth hormone (rhGH) on serum lipids in children treated with chronic peritoneal dialysis. We studied 26 patients aged 5-18 years, including 13 patients treated with rhGH at a dose of 1-1.1 IU/kg per week for 6 months and a control group of 13 patients. Serum total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), HDL-C, triglycerides (TG), apolipoproteins A-I and B-100 (apoA and apoB), lipoprotein (a) [Lp(a)], total protein, albumin, urea, and creatinine levels were measured in all children at baseline and at 1, 3, and 6 months of follow-up. We found a significant increase in the TG level after 1 month of administration of rhGH in the treatment group compared with both baseline (218.8+/-49.2 mg/dl vs. 175.9+/-71.9 mg/dl, respectively, P<0.05) and the control group at 1 month of follow-up (146.5+/-44.3 mg/dl, P<0.001). We found no change in TC, LDL-C, HDL-C, apoA, and Lp(a) levels during treatment with rhGH. These data suggest that administration of rhGH to children treated with peritoneal dialysis results in only a transient increase of serum TG level and has no effect on TC, LDL-C, HDL-C, apoA, and Lp(a) levels.
